• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Efficacy and Safety of Ticagrelor Compared to Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis.
CONCLUSION: The TA treatment in the European and American populations is more beneficial and safer than CA treatment. However, although the Asian population has this benefit, the risk of bleeding is significantly increased as well, and care should be taken when choosing antiplatelet drugs. PMID: 32534561 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - June 13, 2020 Category: Drugs & Pharmacology Authors: Wu H, Xiang X, Li D, Shen S, Li X Tags: Curr Pharm Des Source Type: research

Antithrombotic strategies in patients with atrial fibrillation undergoing percutaneous coronary intervention.
Abstract The optimal strategy of antithrombotic therapy for patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention remains to be a question to be answered. The major challenge in such population is the balance between the benefit of reduced stroke and coronary ischemic events, against the risk of increased bleeding complications. Thus, both thrombotic and bleeding risk assessments should be included into clinical decision-making process for such patients. Currently, there is limited evidence based on randomized trials with adequate power to show the superiority of any strategy in the ...
Source: Current Pharmaceutical Design - December 27, 2017 Category: Drugs & Pharmacology Authors: Pan D, Ren X, Hu Z Tags: Curr Pharm Des Source Type: research

P2Y12 receptor antagonists: which one to choose? A systematic review and meta-analysis.
Conclusion: Newer P2Y12 receptor antagonists are associated with better cardiovascular outcomes in patients with ACS and/or undergoing PCI. Prasugrel use resulted in higher major bleeding rates and no overall mortality benefit compared with clopidogrel. PMID: 27290917 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - June 7, 2016 Category: Drugs & Pharmacology Authors: Briasoulis A, Telila T, Palla M, Siasos G, Tousoulis D Tags: Curr Pharm Des Source Type: research